Asset Details
Do you wish to reserve the book?
Mesenchymal stem cells in the treatment of Cesarean section skin scars: study protocol for a randomized, controlled trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Mesenchymal stem cells in the treatment of Cesarean section skin scars: study protocol for a randomized, controlled trial
Do you wish to request the book?
Mesenchymal stem cells in the treatment of Cesarean section skin scars: study protocol for a randomized, controlled trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Mesenchymal stem cells in the treatment of Cesarean section skin scars: study protocol for a randomized, controlled trial
2018
Overview
Background
Cesarean delivery has already become a very common method of delivery around the world, especially in low-income countries. Hypertrophic scars and wound infections have affected younger mothers and frustrated obstetricians for a long time. Mesenchymal stem cells (MSCs) have strong potential for self-renewal and differentiation to multilineage cells. Previous studies have demonstrated that MSCs are involved in enhancing diabetic wound healing. Therefore, this study is designed to investigate the safety and efficacy of using MSCs in the treatment of Cesarean section skin scars.
Methods
This trial is a prospective, randomized, double-blind, placebo-controlled, single-center trial with three parallel groups. Ninety eligible participants will be randomly allocated to placebo, low-dose (transdermal hydrogel MSCs; 3 × 10
6
cells) or high-dose (transdermal hydrogel MSCs; 6 × 10
6
cells) groups at a 1:1:1 allocation ratio according to a randomization list, once a day for six consecutive days. Study duration will last for 6 months, comprising a 1 week run-in period and 24 weeks of follow-up. The primary aim of this trial is to compare the difference in Vancouver Scar Scale rating among the three groups at the 6th month. Adverse events, including severe and slight signs or symptoms, will be documented in case report forms. The study will be conducted at the Department of Obstetric of Southern Medical University Affiliated Maternal & Child Health Hospital of Foshan.
Discussion
This trial is the first investigation of the potential for therapeutic use of MSCs for the management of women’s skin scar after Cesarean delivery. The results will give us an effective therapeutic strategy to combat Cesarean section skin scars, even with uterine scarring.
Trial registration
ClinicalTrials.gov,
NCT02772289
. Registered on 10 May 2016.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Cell- and Tissue-Based Therapy - adverse effects
/ Cell- and Tissue-Based Therapy - methods
/ Cesarean Section - adverse effects
/ China
/ Cicatrix - prevention & control
/ Clinical Trials, Phase II as Topic
/ Disease
/ Female
/ Humans
/ Medicine
/ Mesenchymal Stem Cells - physiology
/ Methods
/ Protocol
/ Randomized Controlled Trials as Topic
/ Scars
/ Skin
